2Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobaeter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility[J]. Int J Antimierob Agents, 2007, 29(4): 389-396.
3Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin- based triple therapy as second-line treatment for Helicobacter pylori infection [J]. Helicobacter, 2006, 11(1): 46-51.
4Nista EC, Candelli M. Moxifloxaein-based strategies for first-line treatment of Helicobacter pylori infection[J]. AlimentPharmacol Ther, 2005, 21(10): 1241-1247.
5Saccoa F, Spezzaferroa M, Amitranoa M, et al. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment[J]. Dig Liv Dis, 2010, 42(2): 110-114.
6Javier P G, Leticia G, Xavier C. Systematic review and meta-analysis: proton pump inhibitor vs ranitidine bismuth citrate plus two antibiotics in Helicobacterpylori eradication [J]. Helicobacter, 2005, 10 (3): 157-171.
9Saccoa F,Spezzaferroa M,Amitranoa M,et al.Efficacy of fourdifferent moxifloxacin-based triple therapies for first-line H.pyloritreatment[J].Dig Liv Dis,2010,42(2):110.
10Boyanova L,Gergova G,Nikolov R,et al.Prevalence and evolutionof Helicobacter pylori resistance to 6 antibacterial agents over 12years and correlation between susceptibility testing methods[J].DiagnMicrobiol Infect Dis,2008,60(4):409.
